Latest News
BIOSECURE and Catalent deal could bag more biz for Thermo
BIOSECURE and Catalent deal could bag more biz for Thermo
Thermo Fisher Scientific highlighted the BIOSECURE Act and the pending Catalent/Novo deal as potential drivers for its CDMO business during its Q1 earnings call.
Deal-Making
Ingersoll, a provider of industrial solutions, will acquire ILC from investment firm New Mountain Capital to add technologies for life science applications to its arsenal.
Multiply Labs and Stanford Laboratory for Cell and Gene therapy Manufacturing (LCGM) have collaborated to use automation technology for manufacturing cell therapies.
Facilities & Capacity
Higher yields, improved media, and perfusion are driving network optimization at Roche and led to the recent divestment of a 330,000 L California facility to CDMO Lonza.
Merck KGaA has begun construction on an 18,000 square-meter research center at its global headquarters in Darmstadt, Germany.
Global Markets
Thermo Fisher Scientific highlighted the BIOSECURE Act and the pending Catalent/Novo deal as potential drivers for its CDMO business during its Q1 earnings call.
Sartorius has closed its first quarter positively “in line” with expectations but highlights China as a continued market weakness.
Regulations
The US FDA has approved Beqvez (fidanacogene elaparvovec), Pfizer’s adeno-associated virus (AAV) based gene therapy for the treatment of hemophilia B.
CDMO AGC Bio will supply lentiviral vectors for Orchard Therapeutics’ metachromatic leukodystrophy (MLD) gene therapy, approved in the US this week.
Therapeutic Class
Bioprocess vendors have welcomed China’s Stimulus Package as a “positive development,” amid several headwinds driven by dried up funds.
The US FDA has approved Beqvez (fidanacogene elaparvovec), Pfizer’s adeno-associated virus (AAV) based gene therapy for the treatment of hemophilia B.
Upstream & Downstream Processing
Higher yields, improved media, and perfusion are driving network optimization at Roche and led to the recent divestment of a 330,000 L California facility to CDMO Lonza.
Nigel Titchener-Hooker, professor and dean of engineering at University College London, guided delegates at BioProcess International Europe in Vienna, Austria, on a tour through drug-development history.